Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV
in patients with IgG subclass deficiency.
- Will provide data for further collaboration in extending study to involve other
immunological centers in the United States to study patients with similar disease.
Phase:
Phase 2
Details
Lead Sponsor:
The Center for Rheumatic Disease, Allergy, & Immunology
Collaborators:
Grifols Therapeutics Inc. Grifols Therapeutics LLC